Table 3 Comparison of anti-CD-20 antibody as first-line treatment for adult MCD

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | Number of patients | Mean age  (years) | median follow-up  (months) | regimen | PR | CR | Relapses | no remission | AE | Referance |
| Report 1 | 6 | 62.7 | 21.5 | 375mg/m2  4 doses # | 1 | 5 | 0 | 0 | 0 | 11 |
| Report 2 | 9 | 47.6 | 12.5 | 375mg/m2  Once # | 2 | 5 | 1 | 2 | 0 | 10 |
| Our report | 5 | 50 | 29.8 | 1g  Twice \* | 1 | 4 | 1 | 0 | 0 | - |

PR: partial remission; CR:complete remission; AE:adverse events;

# anti-20 antibody is rituximab \* anti-20 antibody is rituximab (4 patients) or obinutuzumab (one patient)